Research & Projects

ESCMID Panorama

Scientific Programme

Wednesday, 21 September 2016

12:00 – 14:30     Registration
Plenary Session 1 (Ballroom)
14:30 – 14:45     ESCMID introductory lecture. Mario Poljak, ESCMID President
14:45 – 15:15     AMR: a global challenge. Barbara Murray
Symposium 1 (Ballroom)
New chemical space: where are new antibiotics coming from?

Chair: Tom Parr
15:15 – 15:45     Antibiotics do not necessarily obey Lipinski's rules. Matt Cooper
15:45 – 16:15     Discovering new antibiotics in nature. Heike Brötz-Osterhelt
16:15 – 16:45     Why target-based drug discovery has not been very successful.
                           Steve Baker
16:45 – 17:15     Getting drugs into Gram-negative bacteria. Mathias Winterhalter
17:30 – 19:00     Welcome reception at the venue (Parkhotel Schönbrunn)

Thursday, 22 September 2016


Plenary Session 2
(Ballroom)
08:00 – 08:30     Drug development within the context of AMR: giving new molecules the
                           best chance. John Rex

Symposium 2 (Ballroom)
Recent advances in regulation to meet the challenge of AMR
Chair: Christa Wirthumer-Hoche
08:30 – 09:00     FDA. Ed Cox
09:00 – 09:30     EMA. Marco Cavaleri
09:30 – 10:00     Common regulatory issues for drug development programmes.
                           Mair Powell


10:00 – 10:30     Coffee Break

Symposium 3 (Ballroom)
In-vitro susceptibility testing and establishing breakpoints for new compounds
Chair: Alasdair MacGowan
10:30 – 11:00     Current tools and approaches for setting breakpoints. Johan Mouton
11:00 – 11:30     Global harmonization of breakpoints – can it be achieved?
                           Gunnar Kahlmeter

11:30 – 12:00     Regulatory issues around test development and validation. Ron Jones
12:00 – 12:30     MIC wild type distributions and ECOFFs and their role in setting clinical
                           breakpoints. John Turnidge

12:30 – 13:30     Lunch

Symposium 4 (Ballroom)
Developing new drugs for AMR in special populations
Chair: Mike Sharland
13:30 – 14:00     Pharmacometrics for special populations. Johannes Van den Anker
14:00 – 14:30     Challenges in developing drugs for critical illness. Jean Chastre
14:30 – 15:00     Addressing therapeutic challenges of AMR in neonates. John Bradley
15:00 – 15:30     Approaches for defining safe and effective regimens for children.
                           Mike Sharland

15:30 – 16:00     Coffee Break

Symposium 5 (Ballroom)
Getting AMR research funded
Chair: Keith Rodvold
16:00 – 16:30     Overview of the current efforts. Herman Goossen
16:30 – 17:00     From big pharma to small and back again. Karen Shaw
17:00 – 18:00     Round table: resources for antibiotic drug discovery.
                           Moderator: David Hooper
                           – MRC. Jonathan Pearce
                           – BARDA. Christopher Houchens
                           – NIH. Francois Franceschi

18:45 – 23:00     Networking dinner:
                           Weinhof Zimmermann
                           Mitterwurzergasse 20
                           1190 Wien
                           www.weinhof-zimmermann.at

Friday, 23 September 2016


Plenary Session 3
(Ballroom)
08:00 – 08:30     Drug discovery within the context of AMR: extending beyond ‘me too’
                           drugs. Tom Parr

Symposium 6 (Ballroom)
Techniques for accelerating and de-risking drug development
Chair: William Hope
08:30 – 09:00    Utilizing PK/PD to increase the probability of successful drug development.
                          Paul Ambrose
09:00 – 09:30    Strength and limitations of pre-clinical models for drug development.
                          Sujata Bhavnani
09:30 – 10:00    Developments in PK/PD modelling and approaches: what to do when the
                          standard model does not describe the data. Elisabet Nielsen
10:00 – 10:30    PK/PD to decrease the development of drug resistance in new molecules.
                          Arnold Louie

10:30 – 11:00    Coffee Break

Symposium 7 (Ballroom)
Innovative clinical trial design for AMR
Chair: Stephan Harbarth
11:00 – 11:30    Real world challenges in performing clinical trials for drug resistant
                          disease. Steve Projan
11:30 – 12:00    Developing drugs in combination. Mike Dudley
12:00 – 12:30    Debate: PK/PD versus frequentist approaches for drug development –
                          Pro. Tom Lodise
12:30 – 13:00    Debate: PK/PD versus frequentist approaches for drug development –
                          Con. Dean Follmann

13:00 – 14:00    Lunch

Interactive Session (Ballroom)
14:00 – 15:00    Interactive Session: Bring questions about your own molecule!
                          Expert panel:
                          - George Drusano, Institute for Therapeutic Innovation, University of Florida
                            (Lake Nona, US)
                          - Mike Dudley, The Medicines Company (San Diego, US)
                          - Arnold Louie, University of Florida, College of Medicine (Orlando, US)
                          - Tom Parr, Spero Therapeutics (Cambridge, US)
                          - David Perlin, Rutgers New Jersey Medical School (Newark, US)
                          - Ursula Theuretzbacher, Center for Anti-Infective Agents (Vienna, AT)
                          You can submit questions for the expert panel HERE.

15:00 – 15:15    Conclusion and closing of the conference (Ballroom)
15:15 – 16:15    Open planning meeting for the 2017 conference in the United States
                          (with wine and cheese, breakout room "Österreich")


CME Accreditation

The conference was granted 13 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

Last update: 30 August 2016

Attendance Grant Application closed

Please do not apply for Attendance Grants for this Course anymore.